Cullinan Oncology (CGEM) Stock Forecast & Price Target

Cullinan Therapeutics is supported by a diversified pipeline with two near-term value drivers: zipalertinib in EGFR exon 20ins NSCLC and CLN-978 in autoimmune disease. Zipalertinib has shown strong clinical efficacy, including a 65% ORR, 14.5-month mPFS, and a 0.50 hazard ratio versus chemotherapy in REZILIENT3, while CNS activity in active brain metastases strengthens differentiation and supports a meaningful commercial opportunity. CLN-978, CLN-049, and velinotamig each add upside through early efficacy signals in large, underserved markets, and the company also stands to receive up to $130 million in milestone payments from Taiho, improving financial optionality.

Cullinan Therapeutics is a clinical-stage biotech with no product revenue and persistently heavy losses, as GAAP operating expenses reached 241.6 and net loss was 219.9 in the cited period, underscoring a capital-intensive model with limited fundamental support. The pipeline remains highly uncertain because its lead programs are still in clinical or preclinical development, and the disclosed safety signals—low immunoglobulins and viral infections in both first patients—raise concerns even where no CRS or ICANS were seen. With diluted weighted average shares at 59.1 to 83.7, the company also faces meaningful dilution risk as it funds ongoing development while EBIT and EPS remain deeply negative.